Abbvie Inc (ABBV)

$208.34 -11.42 (-5.20%)
Market Cap 388.57B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 22.15
Forward PE 15.16
Profit Margin 6.91%
Debt to Equity Ratio -20.91
Volume 8,597,000
Avg Vol 7,122,174
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 3%
Beta 0.34
Analysts Strong Sell
Price Target $249.82

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Guntz
Guntz Mar. 19 at 4:11 PM
$ABBV
0 · Reply
Czreri1
Czreri1 Mar. 19 at 4:00 PM
$ABBV
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 19 at 3:34 PM
$ABBV this is cheap here!
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 19 at 2:58 PM
$SLS $ABBV $XBI @ezimon - I Love when he says, 'because WE TREAT PATIENTS'...
1 · Reply
middleman
middleman Mar. 19 at 2:39 PM
$ABBV oh lord.. hold the line 🥲
1 · Reply
Guntz
Guntz Mar. 19 at 2:26 PM
$ABBV Hopefully when the market bounces at some point that this will move up too. One can hope lol
0 · Reply
NvidiaKing
NvidiaKing Mar. 19 at 11:50 AM
$ABBV piece of shit 💩
0 · Reply
V9RDPUMA
V9RDPUMA Mar. 19 at 10:22 AM
$ABBV Last I checked Rinvoq is also a pill for psoriasis. This J&J approval sell off is just another overeaction.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 18 at 9:49 PM
$SLS "I am totally convinced this prolongation of survival is due to Gps and because we treat patients, ands see these patients, that is why we requested Sellas to allow us to continue treatment with Gps" - we have Miraculous ALL Pooled P3 Survival, Dr's treating actual P3 Patients are on Record stating, "I am totally convinced this prolongation of survival is due to Gps and because we treat patients, ands see these patients, that is why we requested Sellas to allow us to continue treatment with Gps". Meanwhile, Aza+VEN, BAT for Control Arm Patients Recently Failed 3 Large Phase 3 trials conducted by $ABBV - including 2 For AML REMISSION MAINTENANCE. $XBI selloff is offering a Massive Discount. Every SLS Share Holder Guaranteed Massive ROI - up to 47X - when the P3 Results are Announced - and we Conceivably could See them ANY Day Now. Shares are STill Cheap.
1 · Reply
Arcides
Arcides Mar. 18 at 9:21 PM
$ABBV
0 · Reply
Latest News on ABBV
Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 hours ago

Buy Or Fear AbbVie Stock At $210?

Best Dividend Kings: March 2026

Mar 19, 2026, 3:27 AM EDT - 8 hours ago

Best Dividend Kings: March 2026

ABM ABT ADM ADP AWR BDX BKH

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 9 hours ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 21 hours ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 1 day ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 6 days ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Harbor Health Care ETF Q4 2025 Portfolio Review

Mar 11, 2026, 8:18 AM EDT - 8 days ago

Harbor Health Care ETF Q4 2025 Portfolio Review

ABVX GMAB LLY MASI MEDI MRK RVMD

AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 10, 2026, 2:10 PM EDT - 8 days ago

AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 10 days ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 4, 2026, 2:02 AM EST - 15 days ago

AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript

February Dividends With 4 Raises: 1.6% Up To 14.5%

Mar 3, 2026, 8:14 AM EST - 16 days ago

February Dividends With 4 Raises: 1.6% Up To 14.5%

BMY BTI MA

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 16 days ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 17 days ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

Mar 2, 2026, 4:51 AM EST - 17 days ago

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

AMGN AVGO BTI DIV ENB GTY JPM

Best Dividend Aristocrats For March 2026

Feb 27, 2026, 12:21 PM EST - 19 days ago

Best Dividend Aristocrats For March 2026

ABT ADM ADP AFL ALB AMCR AOS

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

Feb 26, 2026, 7:30 AM EST - 21 days ago

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

MRK

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 23 days ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 12:03 PM EST - 23 days ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 23, 2026, 11:00 AM EST - 24 days ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 20, 2026, 2:00 AM EST - 27 days ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 4 weeks ago

AbbVie Declares Quarterly Dividend

AbbVie: Dominating Immunology While Building Oncology Upside

Feb 17, 2026, 1:11 AM EST - 4 weeks ago

AbbVie: Dominating Immunology While Building Oncology Upside

AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Feb 13, 2026, 12:57 PM EST - 4 weeks ago

AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'

Feb 12, 2026, 7:30 AM EST - 5 weeks ago

54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'

AM APH AR ASML AVAV BTU CARR

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 5 weeks ago

AbbVie sues US health agency over Botox price controls

Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 5 weeks ago

Abbvie sues US health agency over Botox

2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 5 weeks ago

2 Urgent Sells And 2 No Brainer Dividend Buys

AEP AMGN BMY ESS HASI HD PFE

Dividend Kings: No Ideal Buys In February's 57

Feb 10, 2026, 9:45 AM EST - 5 weeks ago

Dividend Kings: No Ideal Buys In February's 57

ABM ADP CWT FRT FTS HRL HTO

AbbVie: The Market Is Getting It Wrong

Feb 5, 2026, 8:52 AM EST - 6 weeks ago

AbbVie: The Market Is Getting It Wrong

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

Feb 5, 2026, 4:25 AM EST - 6 weeks ago

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

Feb 4, 2026, 6:04 PM EST - 6 weeks ago

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

Feb 4, 2026, 5:45 PM EST - 6 weeks ago

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

Feb 4, 2026, 3:39 PM EST - 6 weeks ago

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

Feb 4, 2026, 1:20 PM EST - 6 weeks ago

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

Feb 4, 2026, 12:38 PM EST - 6 weeks ago

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 6 weeks ago

AbbVie Revenue Rises on Immunology Growth

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

Feb 4, 2026, 8:18 AM EST - 6 weeks ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Feb 4, 2026, 7:51 AM EST - 6 weeks ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Feb 4, 2026, 7:48 AM EST - 6 weeks ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:50 AM EST - 6 weeks ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Feb 3, 2026, 8:00 AM EST - 6 weeks ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

Jan 29, 2026, 10:30 PM EST - 6 weeks ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABVX CVLT FIX FTAI GKOS GMAB HLI

10 Highest Rated Dividend Kings For Generations Of Income

Jan 29, 2026, 10:10 AM EST - 7 weeks ago

10 Highest Rated Dividend Kings For Generations Of Income

ABM ABT ADM BDX BKH KMB KO

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 29, 2026, 8:00 AM EST - 7 weeks ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 28, 2026, 8:00 AM EST - 7 weeks ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 7 weeks ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Jan 27, 2026, 9:34 AM EST - 7 weeks ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Best Dividend Kings: January 2026

Jan 25, 2026, 10:11 PM EST - 7 weeks ago

Best Dividend Kings: January 2026

ABM ABT ADM ADP AWR BDX BKH

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:43 PM EST - 2 months ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

Jan 16, 2026, 1:35 PM EST - 2 months ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

Guntz
Guntz Mar. 19 at 4:11 PM
$ABBV
0 · Reply
Czreri1
Czreri1 Mar. 19 at 4:00 PM
$ABBV
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 19 at 3:34 PM
$ABBV this is cheap here!
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 19 at 2:58 PM
$SLS $ABBV $XBI @ezimon - I Love when he says, 'because WE TREAT PATIENTS'...
1 · Reply
middleman
middleman Mar. 19 at 2:39 PM
$ABBV oh lord.. hold the line 🥲
1 · Reply
Guntz
Guntz Mar. 19 at 2:26 PM
$ABBV Hopefully when the market bounces at some point that this will move up too. One can hope lol
0 · Reply
NvidiaKing
NvidiaKing Mar. 19 at 11:50 AM
$ABBV piece of shit 💩
0 · Reply
V9RDPUMA
V9RDPUMA Mar. 19 at 10:22 AM
$ABBV Last I checked Rinvoq is also a pill for psoriasis. This J&J approval sell off is just another overeaction.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 18 at 9:49 PM
$SLS "I am totally convinced this prolongation of survival is due to Gps and because we treat patients, ands see these patients, that is why we requested Sellas to allow us to continue treatment with Gps" - we have Miraculous ALL Pooled P3 Survival, Dr's treating actual P3 Patients are on Record stating, "I am totally convinced this prolongation of survival is due to Gps and because we treat patients, ands see these patients, that is why we requested Sellas to allow us to continue treatment with Gps". Meanwhile, Aza+VEN, BAT for Control Arm Patients Recently Failed 3 Large Phase 3 trials conducted by $ABBV - including 2 For AML REMISSION MAINTENANCE. $XBI selloff is offering a Massive Discount. Every SLS Share Holder Guaranteed Massive ROI - up to 47X - when the P3 Results are Announced - and we Conceivably could See them ANY Day Now. Shares are STill Cheap.
1 · Reply
Arcides
Arcides Mar. 18 at 9:21 PM
$ABBV
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 18 at 9:13 PM
$ABBV Share Price: $208.33 Contract Selected: Apr 10, 2026 $210 Calls Buy Zone: $5.02 – $6.20 Target Zone: $9.52 – $11.64 Potential Upside: 79% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Guntz
Guntz Mar. 18 at 8:34 PM
$ABBV Sitting at critical support here. Tomorrow will be important
1 · Reply
biolover
biolover Mar. 18 at 8:14 PM
$VKTX $ABBV down big today after oral IL23 peptide inh approval. Management is relaxed about skyrizi although another reason for them to get big into obesity.
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 18 at 8:11 PM
Shorted $ABBV at $209.03. From Grok: "We stayed in cash due to the short-term downtrend and weak momentum, but today's sharp breakdown below 220 to 207.93 on higher volume changes that so we're now short." https://www.techtrader.ai/grokwall/?post=17053&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
R33dh
R33dh Mar. 18 at 7:16 PM
$ABBV 180s and ill add biggggg
0 · Reply
Guntz
Guntz Mar. 18 at 7:10 PM
$ABBV Picked up 4/24 $230 calls
0 · Reply
profit_guru
profit_guru Mar. 18 at 7:00 PM
$ABBV - tomorrow analysts will Come and pound the table to buy the dip…no competition with JNJ psoriasis pill whatsoever atleast for couple of years …near term 230…imo
0 · Reply
Gebinator
Gebinator Mar. 18 at 6:52 PM
$ABBV it would be worth it for this company to grab RVPH's Brilaroxazine - at least for Schizophrenia. My goodness, the opportunity in the right hands.
0 · Reply
Guntz
Guntz Mar. 18 at 6:44 PM
$ABBV $208 Is good support imo and daily RSI has hit 30. The only times it has broken 30 in the last few years was during Trump tariffs last April and the fail schizo drug in 2024. Major events which I don't believe today is. My opinion at least
0 · Reply
Czreri1
Czreri1 Mar. 18 at 6:40 PM
$ABBV people are acting like Johnson and Johnson got FDA approval. It’s phase 3 so promising but still months if not years away.
1 · Reply
da2021
da2021 Mar. 18 at 5:16 PM
$ABBV why is this down big today?
1 · Reply
BioTechHealthX
BioTechHealthX Mar. 18 at 5:12 PM
$ABT $ABBV $LLY $JNJ $MRK Discover the top 5 healthcare stocks to buy now as Abbott, Merck, AbbVie, Johnson & Johnson, and Eli Lilly gain momentum. From obesity drugs to breakthrough cancer treatments, here’s why these undervalued healthcare stocks could outperform the market in 2026 and beyond. https://biotechhealthx.com/biotech-news/top-5-healthcare-stocks-according-to-goldman-sachs/
0 · Reply